A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium

Exclusion Criteria

• •Medications that, when combined with tryptophan, increase the risk of serotonin syndrome. The classes of medications include:
• •* monoamine oxidase inhibitors
• •* selective serotonin reuptake inhibitors
• •* serotonin-norepinephrine reuptake inhibitors
• •* triptans
• •* opioids
• •* central nervous system stimulants
• •* bupropion
• •* St. John's Wort
• •Patients who undergo an operation on their brain.
• •Factors which prevent delirium assessment with the CAM-ICU: vision impairment or non-fluent English speakers.
• •A lowered seizure threshold including:
• •* history of seizure disorder
• •* alcohol abuse defined by a high AUDIT score (\>8 females and \>13 males)
• •* benzodiazepine or barbiturate abuse within three months of the study
• •* OR a positive urine toxicology screen for alcohol, benzodiazepines or barbiturates.
• •Significant liver disease (Child's class B or greater) or significant renal disease (Creatinine ≥2.0).
• •History of Huntington's or Addison's disease. (As requested by the FDA)
• •History of bipolar disorder or a psychotic disorder (such as a psychotic major depression, schizophrenia, schizoaffective disorder, or psychosis in Alzheimer's disease or other dementia). (As requested by the FDA)
• •Women who are not post-menopausal. (As requested by the FDA)